A Pilot Study to Evaluate Radiotherapy-Induced Anti-Tumor Immunity in Metastatic Carcinoma of the Pancreas

NCT ID: NCT01985958

Last Updated: 2020-04-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-07-31
• Study Completion Date: 2019-12-31

Brief Summary

Primary Objective: To estimate the rate at which radiotherapy to the primary or a metastatic lesion produces an immune response in patients with metastatic carcinoma of the pancreas.

Secondary Objectives: To characterize the kinetics of an immune response induced by radiotherapy. To characterize the dependency of the immune response on prior exposure to chemotherapy.

Conditions

Histological or Cytological Diagnosis of Pancreatic Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC

Study Groups

Single arm

In this trial, we will deliver low-dose (8Gy in a single fraction) radiotherapy (SBRT or any other acceptable delivery method as determined by the treating physician) for palliation of symptoms in patients in whom it is clinically indicated. This dose is far lower than what has been used in the definitive settings described above. This is a safe dose, and is entirely consistent with the dose range used for routine palliation. Therefore, this trial does not involve an experimental intervention; the research aspect of this protocol is the evaluation of the immune response to clinically indicated palliative radiotherapy.

Group Type: EXPERIMENTAL

Radiation therapy

Intervention Type: DEVICE

Interventions

Radiation therapy

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Histological or cytological diagnosis of pancreatic carcinoma
• Patients ≥ 18 years of age
• Eastern Cooperative Oncology Group (ECOG) performance status 0,1,or 2
• Patients must have distant metastatic disease (stage 4)
• Satisfactory organ and bone marrow function as defined by: Absolute neutrophil count> 1,000/uL, Platelets > 75,000uL Hemoglobin > 9 Bilirubin ≤ 2.0x the institutional normal upper limit unless secondary to bile duct obstruction by tumor,
• Creatinine ≤ 1.5x the institutional normal upper limit
• Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5x the institutional normal upper limit.
• A clinical recommendation for radiotherapy to the primary or a metastatic lesion had been made.
• Must be able to provide informed consent.

Exclusion Criteria

• No prior radiation to the area planned for radiotherapy
• Active invasive cancer other than pancreatic adenocarcinoma. Non-melanoma skin cancer, superficial cervical or bladder cancer and prostate cancer with PSA level < 1.0 are not excluded.
• Known HIV, HCV and/or HBV positive (by patient report/medical record)
• Patients with ongoing or active infection
• Planned concurrent treatment with systemic high dose corticosteroids.
• Received an anticancer treatment (systemic therapy or radiation therapy)within 21 days prior to enrollment.
• Immunotherapy (e.g. monoclonal antibodies)within 21 days prior to enrollment.
• Immunosuppressive therapies (e.g. steroids, cyclosporine) are not permitted.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abramson Cancer Center at Penn Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Edgar Ben-Josef, MD

Role: PRINCIPAL_INVESTIGATOR

Abramson Cancer Center at Penn Medicine

Locations

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Countries

United States

Other Identifiers

UPCC 14213

Identifier Type: -

Identifier Source: org_study_id